Taletrectinib (DS-6051b)
$200.00
CAS No.: 1505515-69-4
Catalog No.: 193685
Purity: 95%
MF: C29H34FN5O5
MW: 551.619
Storage: 2-8 degree Celsius
SMILES: C(CCCCC(=O)O)(=O)O.N[C@@H](COC1=CC=C(C=C1)C1=CN=C2N1N=C(C=C2)N[C@H](C)C2=CC(=CC=C2)F)C
Catalog No.: 193685
Purity: 95%
MF: C29H34FN5O5
MW: 551.619
Storage: 2-8 degree Celsius
SMILES: C(CCCCC(=O)O)(=O)O.N[C@@H](COC1=CC=C(C=C1)C1=CN=C2N1N=C(C=C2)N[C@H](C)C2=CC(=CC=C2)F)C
Taletrectinib (DS-6051b); 3-(4-((R)-2-aminopropoxy)phenyl)-N-((R)-1-(3-fluorophenyl)ethyl)imidazo[1,2-b]pyridazin-6-amine adipate; CAS No.: 1505515-69-4; Taletrectinib (DS-6051b). PROPERTIES: Taletrectinib (DS-6051b) is a white to off-white powder with the molecular formula C29H27N5O3. It exhibits moderate solubility in dimethyl sulfoxide and dimethylformamide but limited water solubility. The compound is stable at temperatures below 30 C and requires storage in a tightlyCAS No.: 1550371-22-6; BMS-P5. PROPERTIES: BMS-P5 is a crystalline compound with the molecular formula C24H22F3N5O3. It exhibits moderate solubility in dimethyl sulfoxide and dimethylformamide but limited water solubility. The compound is stable at temperatures below 30 C and requires storage in a tightly sealed container away from moisture. Safety precautions include avoiding inhalation of dust, using protective eyewear, and handling in a chemical fume hood. With a molecular weight of approximately 511.46 g/mol, it demonstrates moderate metabolic stability and favorable pharmacokinetic properties. The compound has multiple fluorine atoms that contribute to its binding affinity and metabolic resistance. Its logP value around 2.7 indicates a balance between solubility and membrane permeability. APPLICATIONS: BMS-P5 functions as a potent and selective inhibitor of the Bruton's tyrosine kinase (BTK), investigated for the treatment of B-cell malignancies and autoimmune diseases. In preclinical research, it is used to study BTK's role in B-cell receptor signaling and to develop novel therapeutic approaches. The compound is employed in combination studies with other targeted therapies to enhance antitumor efficacy. Additionally, it serves as a research tool in immunology to investigate B-cell biology and in drug discovery to explore structure-activity relationships of BTK inhibitors. According to "Bruton's Tyrosine Kinase as a Therapeutic Target in Oncology and Immunology," BMS-P5 provides a valuable platform for targeting BTK-mediated signaling pathways.
Reviews
Write Your Own Review